Abbott India Q3 Results: ₹17.24 Billion Revenue, ₹3.76 Billion Profit

Abbott India Ltd, a leading pharmaceutical and healthcare company, announced its Q3 FY26 results, showcasing steady growth momentum. The company posted consolidated revenue of ₹17.24 billion and net profit of ₹3.76 billion, underscoring its ability to balance innovation, efficiency, and market expansion in a competitive healthcare landscape.

Key Highlights

• Revenue from Operations: ₹17.24 billion in Q3 FY26.
• Net Profit: ₹3.76 billion, supported by strong demand across therapeutic categories.
• Growth Drivers: Expansion in chronic therapies, nutritional products, and specialty care.
• Operational Efficiency: Improved margins through cost optimization and supply chain resilience.
• Sector Context: India’s pharmaceutical industry continues to benefit from rising healthcare demand and government initiatives.
• Strategic Outlook: Abbott India aims to strengthen its portfolio with new product launches and expand its reach in Tier-II and Tier-III cities.

The results highlight Abbott India’s resilience and growth trajectory, positioning it as a key player in India’s evolving healthcare ecosystem.

Sources: Business Standard, The Economic Times, Moneycontrol